logo
  Join        Login             Stock Quote

Perrigo (PRGO): FDA Approves Testosterone Gel 1%

 February 05, 2013 02:06 PM
 


(By Balachander) Perrigo Co. (NASDAQ: PRGO) said it has received approval from the U.S. health regulators for its New Drug Application (NDA) for testosterone gel 1%.

The Allegan, Michigan-based developer of over-the-counter (OTC) drugs said its NDA included a bioequivalence study that compared its product to AbbVie's AndroGel 1%.

AndroGel 1% (testosterone gel 1%) is indicated to treat adult males who have low or no testosterone. As measured by Symphony Health, annual sales were roughly $705 million.

"This filing is another example of our investment in new products and continued focus on bringing extended topicals to market," said Perrigo CEO Joseph Papa.

[Related -Japan Surges Near 5-Year Highs]

Last week, the company launched clobetasol emulsion propionate foam, 0.05%, the generic equivalent  of Olux -E Foam, 0.05%. Clobetasol emulsion propionate foam, 0.05% is indicated to treat moderate to severe dermatosis of the scalp.

On Tuesday, shares gained 1.45% to trade at $107.28. In the past 52-weeks, the stock has been trading between $90.18 and $120.78.

iOnTheMarket Premium
Advertisement

Advertisement


Post Comment -- Login is required to post message
Name:  
Alert for new comments:
Your email:
Your Website:
Title:
Comments:
 

rss feed

Latest Stories

article imageBuffett's Market Indicator Flashes Red, Prepare To Sell

With each passing month, it's becoming evident that the current bull market has slowed from a gallop to a read on...

article imagePBoC joins other major central banks with unconventional monetary policy action

Softer than expected economic growth in China (see discussion) has finally spurred the PBoC into action. read on...

article imageA Buyback Boost?

Are stock buybacks the only thing keeping this bull market read on...

article imageGold Slides On Perfect Storm For Dollar

For all the anticipation surrounding the delivery of the Fed’s statement in the run-up to the September read on...

Advertisement
Popular Articles

Advertisement
Daily Sector Scan
Partner Center

Related Articles:

The Truth About The Impact Of Dividend Reinvesting
More Articles on: Medical



Fundamental data is provided by Zacks Investment Research, and Commentary, news and Press Releases provided by YellowBrix and Quotemedia.
All information provided "as is" for informational purposes only, not intended for trading purposes or advice. iStockAnalyst.com is not an investment adviser and does not provide, endorse or review any information or data contained herein.
The blog articles are opinions by respective blogger. By using this site you are agreeing to terms and conditions posted on respective bloggers' website.
The postings/comments on the site may or may not be from reliable sources. Neither iStockAnalyst nor any of its independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. You are solely responsible for the investment decisions made by you and the consequences resulting therefrom. By accessing the iStockAnalyst.com site, you agree not to redistribute the information found therein.
The sector scan is based on 15-30 minutes delayed data. The Pattern scan is based on EOD data.